Expression of matrix metalloproteinases and their inhibitors during the resorption of schistosome egg-induced fibrosis in praziquantel-treated mice

Immunology

Volumn 111, Issue 3, 2004, Pages 343-352

  Singh, Kameshwar P ^a   Gerard, Herve C ^a   Hudson, Alan P ^a   Boros, Dov L ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 4; COLLAGENASE 3; CYTOKINE; GELATINASE A; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; NEUTROPHIL COLLAGENASE; NITRIC OXIDE SYNTHASE; PRAZIQUANTEL; STROMELYSIN; STROMELYSIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASSOCIATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; EGG; FEMALE; GENE EXPRESSION; GRANULOMA; LIVER FIBROSIS; MOUSE; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SPLEEN CELL; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT OUTCOME; WORM;

ANIMALS; ANTHELMINTICS; BODY WEIGHT; CELL COUNT; CELLS, CULTURED; COLLAGEN; CYTOKINES; FEMALE; GENE EXPRESSION; HYDROXYPROLINE; LIVER; LIVER CIRRHOSIS; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED CBA; ORGAN SIZE; PRAZIQUANTEL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SCHISTOSOMIASIS MANSONI; SPLEEN; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 1642302147     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0019-2805.2004.01817.x     Document Type: Article

References (48)

1. WHO. Public health impact of schistosomiasis: disease and mortality. WHO Expert Committee on the Control of Schistosomiasis. Bull World Health Organ 1993; 71:657-62.
2. Weinstock JV. The pathogenesis of granulomatous inflammation and organ injury in schistosomiasis: interactions between schistosome ova and the host. Immunol Invest 1992; 21:455-75.
3. Bica I, Hamer DH, Stadecker MJ. Hepatic schistosomiasis. Infect Dis Clin North Am 2000; 14:583-604.
4. Zwingenberger K, Harma G, Feldmeier H, Muller O, Steiner A, Bienzle U. Liver involvement in human schistosomiasis mansoni. Regression of immunological and biochemical disease markers after specific treatment. Acta Trop 1988; 45:263-75.
5. Homeida MA, Tom IE, Nash T, Bennett JL. Association of the therapeutic activity of praziquantel with the reversal of Symmers' fibrosis induced by Schistosoma mansoni. Am J Trop Med Hyg 1991; 45:360-5.
6. Doehring-Schwerdtfeger E, Abdel-Rahim IM, Kardorff R et al. Ultrasonographical investigation of periportal fibrosis in children with Schistosoma mansoni infection: reversibility of morbidity twenty-three months after treatment with praziquantel. Am J Trop Med Hyg 1992; 46:409-15.
7. Dunn MA, Kamel R, Kamel IA et al. Liver collagen synthesis in schistosomiasis mansoni. Gastroenterology 1979; 76:978-82.
8. Takahashi S, Dunn MA, Seifter S. Liver collagenase in murine schistosomiasis. Gastroenterology 1980; 78:1425-31.
9. Warren KS. The influence of treatment on the development and course of murine hepatosplenic schistosomiasis mansoni. Trans R Soc Trop Med Hyg 1962; 56:510-9.
10. Cameron GR, Ganguly NC. An experimental study of the pathogenesis and reversibility of schistosomal hepatic fibrosis. J Pathol Bacteriol 1964; 87:217-37.
11. Morcos SH, Khayyal MT, Mansour MM, Saleh S, Ishak EA, Girgis NI, Dunn MA. Reversal of hepatic fibrosis after praziquantel therapy of murine schistosomiasis. Am J Trop Med Hyg 1985; 34:314-21.
12. Andrade ZA, Cox TM, Cheever AM. Regression of hepatic lesions after treatment of Schistosoma mansoni or Schistosoma japonicum infection in mice: a comparative study. Am J Trop Med Hyg 1993; 49:1-9.
13. Warren KS, Klein L. Chronic murine hepatosplenic schistosomiasis mansoni: relative irreversibility after treatment. Trans R Soc Trop Med Hyg 1969; 63:333-7.
14. Andrade ZA, Grimaud JA. Evolution of the schistosomal hepatic lesions in mice after curative chemotherapy. Am J Pathol 1986; 124:59-65.
15. Andrade ZA, Grimaud J. Morphology of chronic collagen resorption: a study on the late stage of schistosomal granuloma involution. Am J Pathol 1988; 132:389-99.
16. Emonard H, Grimaud JA. Active and latent collagenase activity during reversal of hepatic fibrosis in murine schistosomiasis. Hepatology 1989; 10:77-83.
17. Biempica L, Takahashi S, Biempica S, Kobayashi M. Immunohistochemical localization of collagenase in hepatic murine schistosomiasis. J Histochem Cytochem 1983; 31:488-94.
18. El-Badrawy NM, Abdel Hadi AM, Voss B, Metwally AA, Ebeid F. Effect of praziquantel on the distribution of interstitial collagen types I and III and basement membrane collagen types IV and V in murine hepatic schistosomiasis. Trans R Soc Trop Med Hyg 1991; 85:752-5.
19. Arthur MJP. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2000; 279: G245-9.
20. McCrudden R, Iredale JP. Liver fibrosis, the hepatic stellate cell and tissue inhibitors of metalloproteinases. Histol Histopathol 2000; 15:1159-68.
21. Boros DL, Warren KS. Delayed hypersensitivity granuloma formation and dermal reaction induced and elicited by a soluble factor isolated from Schistosoma mansoni eggs. J Exp Med 1970; 132:448-507.
22. Bergman I, Loxley R. Two improved and simplified methods for the spectrophotometric determination of hydroxyproline. Anal Chem 1963; 35:1961-5.
23. Reddy GK, Envenemeka CS. A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem 1996; 29: 225-9.
24. Gerard HC, Wang Z, Whittum-Hudson JA, El-Gabalawy H, Goldbach-Mansky R, Bardin T, Schumacher HR, Hudson AP. Cytokine and chemokine mRNA produced in synovial tissue chronically infected with Chlamydia trachomatis and C. pneumoniae. J Rheumatol 2002; 29:1827-35.
25. Gerard HC, Branigan PJ, Schumacher HR Jr, Hudson AP. Synovial Chlamydia trachomatis in patients with reactive arthritis/Reiter's syndrome are viable but show aberrant gene expression. J Rheumatol 1998; 25:734-42.
26. Woessner JF Jr. The matrix metalloproteinase family. In: Parks WC, Mecham RP, eds. Matrix Metalloproteinases. New York: Academic Press, 1998:1-14.
27. Pender SL, Fell JM, Chamow SM, Ashkenazi A, MacDonald TT. A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production. J Immunol 1998; 160:4098-5103.
28. Seeland U, Haeuseler C, Hinrichs R, Rosenkranz S, Pfitzner T, Scharffetter-Kochanek K, Bohm M. Myocardial fibrosis in transforming growth factor-beta (1) TGF-beta (1) transgenic mice is associated with inhibition of interstitial collagenase. Eur J Clin Invest 2002; 32:295-303.
29. Knittel T, Mehde M, Kobold D, Saile B, Dinter C, Ramadori G. Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-α and TGF-β1. J Hepatol 1999; 30:48-60.
30. Gardner CR, Laskin JD, Dambach DM et al. Reduced hepatotoxicity of acetaminophen in mice lacking inducible nitric oxide synthase: potential role of tumor necrosis-alpha and interleukin-10. Toxicol Appl Pharmacol 2002; 184:27-36.
31. Dupre L, Herve M, Schacht A-M, Capron A, Riveau G. Control of schistosomiasis pathology by combination of Sm27GST DNA immunization and praziquantel treatment. J Infect Dis 1999; 180: 454-63.
32. Murphy G, Cockett MI, Ward RV, Docherty AJ. Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). Biochem J 1991; 277:277-9.
33. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997; 74:111-22.
34. Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, Pawley S, Hovell C, Arthur MJP. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998; 102:538-49.
35. Vaillant B, Chiaramonte MG, Cheever AW, Soloway PD, Wynn TA. Regulation of hepatic fibrosis and extracellular matrix genes by the Th response: new insight into the role of tissue inhibitors of matrix metalloproteinases. J Immunol 2001; 167: 7017-26.
36. Truden JL, Boros DL. Collagenase, elastase, and non-specific protease production by vigorous or immunomodulated liver granulomas and granuloma macrophages/eosinophils of S. mansoni-infected mice. Am J Pathol 1985; 121:166-75.
37. Chiaramonte MG, Donaldson DD, Cheever AW, Wynn TA. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest 1999; 104:777-85.
38. Fallon PG, Richardson EJ, McKenzie GJ, McKenzie AN. Schistosome infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent. J Immunol 2000; 164:2585-91.
39. Czaja MJ, Weiner FR, Takahashi S, Giambrone M-A, van der Meide PH, Schellekens H, Biempica L, Zern MA. γ-Interferon treatment inhibits collagen deposition in murine schistosomiasis. Hepatology 1993; 10:795-800.
40. Wynn TA, Cheever AW, Jankovic D, Poindexter RW, Caspar P, Lewis FA, Sher A. An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection. Nature 1995; 376:594-6.
41. Kolb M, Bonniaud P, Galt T, Sime PJ, Kelly MM, Margetts PJ, Gauldie J. Differences in the fibrogenic response after transfer of active transforming growth factor-β1 gene to lungs of 'fibrosis-prone' and 'fibrosis- resistant' mouse strains. Am J Respir Cell Mol Biol 2002; 27:141-50.
42. Brunet LR, Beau M, Dunne DW, Pearce EJ. Nitric oxide and the Th2 response combine to prevent severe hepatic damage during Schistosoma mansoni infection. J Immunol 1999; 163:4976-84.
43. Hesse M, Cheever AW, Jankovic D, Wynn TA. NOS-2 mediates the protective anti-inflammatory and antifibrotic effects of the Th1-inducing adjuvant, IL-12, in a Th2 model of granulomatous disease. Am J Pathol 2000; 157:945-55.
44. Roberts M, Butterworth AE, Kimani G, Kamau T, Fulford AJC, Dunne DW, Ouma JH, Sturrock RF. Immunity after treatment of human schistosomiasis: association between cellular responses and resistance to reinfection. Infect Immun 1993; 61:4984-93.
45. Zwingenberger K, Irschick E, Siqueira Vergetti JG, Correia Dacal AR, Janssen-Rosseck R, Bienzle U, Huber C, Feldmeier H. Release of interleukin 2 and gamma interferon by peripheral mononuclear cells in human Schistosoma mansoni infection normalizes after chemotherapy. Scand J Immunol 1998; 30:463-71.
46. Boros DL, Whitfield JR. Endogenous IL-10 regulates IFN-γ and IL-5 cytokine production and the granulomatous response in schistosomiasis mansoni-infected mice. Immunology 1998; 94:481-7.
47. El-Badrawy NM, Hassanein HI, Botros SS, Nagy FM, Abdallah NM, Herbage D. Effect of praziquantel on hepatic fibrosis in experimental schistosomiasis mansoni. Exp Mol Pathol 1988; 49:151-60.
48. Last JA, King TE Jr, Nerlich AG, Reiser KM. Collagen cross-linking in adult patients with acute and chronic fibrotic lung disease. Am Rev Respir Dis 1990; 141:307-13.